Imidazo[4,5-b] pyridine compound and pharmaceutical composition thereof for the treatment of inflammatory disorders

Abstract

The present invention discloses compound according to Formula I: wherein Cy is phenyl, or 5-6 membered heteroaryl comprising one, two or three N atoms; L1 is a single bond, -O-, -C(=O)-, -C(=O)O-, -S(O)2-, -NR6a -, C(=O)NR6b-, -S(O)2NR6c-, or -C(=O)NR6dS(O)2-; R1 is: - H, - C1-6 alkyl optionally substituted with one or more independently selected o OH, o halo, o C1-4 alkoxy, o -NR7aR 7b , o -C(=O)OH-, o -C(=O)NR7cR 7d , o -C(=O)OC1-4 alkyl, or o 4-8 membered monocyclic heterocycloalkyl comprising one, two, or three heteroatoms independently selected from N, S, and O; - C3-7 cycloalkyl optionally substituted with one or more OH, C1-4 alkoxy, or - 4-9 membered monocyclic or spirobicyclic or bridged or fused bicyclic heterocycloalkyl comprising one, two, or three heteroatoms independently selected from N, S, and O; which heterocycloalkyl is optionally substituted with one or more independently selected R11 groups; R 2 is - halo, - CN, or - C1-4 alkyl; the subscript n is 0, or 1; L 2 is O, or -NR4 -, R 3 is - C1-6 alkyl optionally substituted with one or more independently selected o halo, or o C3-7 cycloalkyl, - Phenyl substituted with one R5a group and one or two independently selected R5b groups, - 6-membered heteroaryl comprising one or two N atoms, substituted with one R5a group and one or two independently selected R5b groups, - 4-10 membered monocyclic or fused, bridged or spiro bicyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, S, and O, optionally substituted with one, two or three groups independently selected from R5a and R5b, or - 4-10 membered monocyclic or fused, bridged or spiro bicyclic cycloalkyl, optionally substituted with one, two or three groups independently selected from R5a and R5b; The present invention relates to compound, method for its production, pharmaceutical composition comprising the same, for use in the prophylaxis and / or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and / or diseases associated with hypersecretion of IFNα, IL12 and / or IL23 by administering the compound of the invention.